We have developed a mouse model with a humanized liver to improve the translational capabilities of your drug discovery and development projects.
We specialize in advancing drug discovery and early development projects with our quality-controlled study services using PXB-mice and PXB-cells®.
Perform preclinical drug testing experiments with greater translational relevance than ever before with our chimeric mouse model that possesses human liver characteristics.
Innovation starts with the PXB-mouse®.
Get invaluable insights into human outcomes with the PXB-mouse®, a chimeric mouse model with a humanized liver that is repopulated by human hepatocytes.
Advance your in vitro studies with the use of PXB-cells®, our primary human hepatocytes freshly isolated from the PXB-mouse®.
Our PXB-mouse® is the world’s most widely used humanized liver mouse model for drug development. With our stable and consistent production line, we rigorously select top-quality PXB-mice with a humanized condition to suit your research demands.
Number of Academic Conference Presentations
Number of Scientific Papers
Harness the power of PXB-mice and PXB-cells® to boost the translational quality of your varied drug discovery and development projects.
Demonstrate human outcomes in gene editing and gene-based therapeutic research studies.
Overcome research translation challenges affecting the development of therapeutic agents.
Demonstrate antiviral efficacy and tolerability in best-in-class therapeutics for Hepatitis B virus.
Predict human outcomes more accurately to enable the development of safe, effective, and compliant drugs.
Employ the services of our technical team to transplant and engraft hepatocytes into our proprietary model.
At PhoenixBio, we help our customers to deliver on their drug discovery and development projects with our contract study services using PXB-mice. Our experts have over 10 years of experience and will provide professional technical support from study planning and design to the delivery of the final report.
15 September 2025
The Congress of the European Societies of Toxicology is organizing EuroTox 2025 to focus on this year's theme...
11 September 2025
Gene editing promises cures for a wide range of diseases. Zinc-finger nucleases (ZFNs) were developed as the first...
19 August 2025
Oligonucleotide therapeutics have shown promise as a diverse treatment option for a wide range of diseases. Developing...
Contact us to find out how the PhoenixBio team could help your drug discovery and development projects today.